Beneficial effects of high-dose losartan in IgA nephritis

Clinical Nephrology

Volumn 71, Issue 6, 2009, Pages 617-624

  Woo, Keng Thye ^a   Chan, C M ^a   Tan, H K ^a   Choong, H L ^a   Foo, M ^a   Vathsala, A ^a   Lee, E J C ^b   Tan, C C ^c   Lee, G S L ^c   Tan, S H ^a   Lim, C H ^a   Chiang, G S C ^a   Fook Chong, S ^a,b   Wong, S K S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

ACEI; ARB; Glomerular filtration rate; Proteinuria; Renal failure; Treatment

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; LOSARTAN; MALE; TREATMENT OUTCOME;

EID: 67651123324     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71617     Document Type: Article

References (19)

1. Adamczak M, Gross ML, Amann K et al. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol. 2004; 15: 3063-3072.
2. Aranda P, Segura J, Ruilope LM et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis. 2005; 46: 1074-1079.
3. Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol. 2007; 18 (11): 2806-2809.
4. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med. 2006; 119: 405-475.
5. Fogo AB. Can glomerulosclerosis be reversed? Nat Clin Pract Nephrol. 2006; 2: 290-291.
6. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in Type 2 diabetes mellitus. J Hypertens. 2007; 25: 1921-1926.
7. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotension inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005; 16: 966-976.
8. Mahmood J, Khan F, Okada S et al. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int. 2006; 70: 1591-1959.
9. Marinides GN, Groggel GC, Cohen AH et al. Enalapril and low protein reverse chronic puromycin amino-nucleoside nephropathy. Kidney Int. 1990; 37: 749-757.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med. 2001; 345: 870-878.
11. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephritis with ACE inhibitors: a ramdomised and controlled trial. J Am Soc Nephrol. 2003; 14: 1578-1583.
12. Remuzzi G, Remuzzi A. Is regression of chronic nephropathies a therapeutic target? J AmSoc Nephrol. 2005; 16: 840-842.
13. Remuzzi A, Gagliardini E et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 2006; 69: 1124-1130.
14. Rossing K, Schjoedt KJ, Jensen BR et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with Type 2 diabetes and microalbuminuria. Kidney Int. 2005; 68: 1190-1198.
15. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999; 10: 997-1006.
16. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: Apost hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001; 12: 2832-2837.
17. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001; 357: 1601-1608.
18. Woo KT, Lau YK, Chan CM et al. ATRA therapy restores normal renal function and renal reserve and prevents renal failure.Ann AcadMedSingapore. 2005; 34: 52-59.
19. Woo KT, Lau YK, Wong KS et al. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgAnephritis. Kidney Int. 2000; 58: 2485-2491.